The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Hepatitis B, Chronic* ; Hepatitis D, Chronic* ; MicroRNAs*/genetics; Humans ; Hepatitis B virus/physiology ; Hepatitis B e Antigens ; Hepatitis B Surface Antigens

miRNAs circulating in whole serum and HBsAg-particles are differentially expressed in chronic hepatitis B (CHB) and HBeAg-negative-HBV infection (ENI); their profiles are unknown in chronic hepatitis D (CHD). Serum- and HBsAg-associated miRNAs were analyzed in 75 subjects of 3 well-characterized groups (CHB 25, CHD 25, ENI 25) using next-generation sequencing (NGS). Overall miRNA profiles were consonant in serum and HBsAg-particles but significantly different according to the presence of hepatitis independently of Hepatitis D Virus (HDV)-co-infection. Stringent (Bonferroni Correction < 0.001) differential expression analysis showed 39 miRNAs upregulated in CHB vs. ENI and 31 of them also in CHD vs. ENI. miRNA profiles were coincident in CHB and CHD with only miR-200a-3p upregulated in CHB. Three miRNAs (miR-625-3p, miR-142-5p, and miR-223-3p) involved in immune response were upregulated in ENI. All 3 hepatocellular miRNAs of MiR-B-Index (miR-122-5p, miR-99a-5p, miR-192-5p) were overexpressed in both CHB and CHD patients. In conclusion, CHD and CHB patients showed highly similar serum miRNA profiling that was significantly different from that of individuals with HBeAg-negative infection and without liver disease.

Curr Opin Chem Biol. 2019 Aug;51:11-17. (PMID: 30825741)
Cancers (Basel). 2019 Nov 11;11(11):. (PMID: 31717959)
Gut. 2021 Apr;70(4):784-795. (PMID: 33127832)
J Med Virol. 2018 Oct;90(10):1586-1592. (PMID: 29896794)
J Leukoc Biol. 2018 Sep;104(3):515-524. (PMID: 29969525)
J Viral Hepat. 2011 Jul;18(7):e242-51. (PMID: 21692939)
Gastroenterology. 1991 Dec;101(6):1649-55. (PMID: 1955130)
Curr Top Microbiol Immunol. 2006;307:47-65. (PMID: 16903220)
Oncol Rep. 2011 Nov;26(5):1281-6. (PMID: 21725618)
J Virol. 2014 May;88(10):5742-54. (PMID: 24623409)
Cancer Res. 2010 Dec 1;70(23):9798-807. (PMID: 21098710)
Mol Immunol. 2022 Jan;141:21-32. (PMID: 34785326)
Ann Intern Med. 1983 Apr;98(4):437-41. (PMID: 6340574)
J Clin Oncol. 2011 Dec 20;29(36):4781-8. (PMID: 22105822)
Viruses. 2020 Jun 16;12(6):. (PMID: 32560053)
J Hepatol. 2010 May;52(5):658-64. (PMID: 20346531)
Hepatology. 2006 Jan;43(1):100-7. (PMID: 16323213)
PLoS One. 2014 Sep 19;9(9):e107986. (PMID: 25238238)
Gut. 2019 Jan;68(1):150-157. (PMID: 29217749)
PLoS One. 2012;7(10):e47490. (PMID: 23091627)
J Hepatol. 1987 Dec;5(3):274-81. (PMID: 3429834)
Front Microbiol. 2021 Jun 21;12:652962. (PMID: 34234753)
Virus Evol. 2019 Jul 15;5(2):vez021. (PMID: 31321078)
Biostatistics. 2008 Apr;9(2):321-32. (PMID: 17728317)
Viruses. 2022 Aug 10;14(8):. (PMID: 36016371)
Hepatology. 1995 Feb;21(2):333-9. (PMID: 7843702)
Nat Commun. 2019 May 8;10(1):2098. (PMID: 31068585)
PLoS One. 2012;7(3):e31952. (PMID: 22470417)
Pathol Res Pract. 2017 Dec;213(12):1464-1469. (PMID: 29103765)
PLoS One. 2017 Aug 30;12(8):e0183828. (PMID: 28854245)
J Virol. 1988 Dec;62(12):4439-44. (PMID: 3184270)
PLoS One. 2014 Oct 28;9(10):e110782. (PMID: 25350115)
Viruses. 2021 Jun 23;13(7):. (PMID: 34201626)
Viruses. 2022 Jul 30;14(8):. (PMID: 36016312)
Hepatology. 2008 Dec;48(6):1810-20. (PMID: 19030170)
J Hepatol. 2015 Apr;62(4):956-67. (PMID: 25595883)
J Virol. 1986 Jun;58(3):945-50. (PMID: 3701932)
Cell Microbiol. 2017 May;19(5):. (PMID: 27886437)
Methods Mol Biol. 2017;1580:21-44. (PMID: 28439824)
Oncotarget. 2018 Jul 06;9(52):29857-29868. (PMID: 30042818)
Genome Biol. 2010;11(3):R25. (PMID: 20196867)
J Viral Hepat. 2021 Jan;28(1):213-216. (PMID: 32852870)
J Virol. 2008 Feb;82(3):1118-27. (PMID: 18032511)
Curr Top Microbiol Immunol. 2006;307:67-89. (PMID: 16903221)
FASEB J. 2011 Dec;25(12):4511-21. (PMID: 21903935)
J Hepatol. 2012 Jan;56(1):115-22. (PMID: 21762665)
Liver Int. 2017 Nov;37(11):1622-1631. (PMID: 28296013)
J Hepatol. 2015 Feb;62(2):448-57. (PMID: 25308172)
J Hepatol. 2016 Apr;64(4):800-6. (PMID: 26678008)
J Virol. 1994 Sep;68(9):5344-50. (PMID: 8057418)
Gastroenterology. 2010 Aug;139(2):483-90. (PMID: 20451520)
Hepatology. 1991 Mar;13(3):413-6. (PMID: 1999312)
Nat Rev Genet. 2019 Nov;20(11):675-691. (PMID: 31395983)
Sci Rep. 2016 Oct 13;6:34740. (PMID: 27734898)
Semin Liver Dis. 1986 Feb;6(1):28-33. (PMID: 3520830)
Ann Palliat Med. 2020 Sep;9(5):3222-3234. (PMID: 32921119)
J Viral Hepat. 2018 Aug;25(8):911-919. (PMID: 29577518)
Hepatology. 2017 Dec;66(6):1826-1841. (PMID: 28992360)
Hepatology. 2012 Mar;55(3):730-41. (PMID: 22105316)
J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875)
Front Oncol. 2022 Jun 29;12:822760. (PMID: 35847904)

Keywords: HBV-DNA; HDV-RNA; Hepatitis B Virus; Hepatitis D Virus; MiR-B-Index

0 (Hepatitis B e Antigens)
0 (Hepatitis B Surface Antigens)
0 (MicroRNAs)
0 (MIRN625 microRNA, human)

Date Created: 20231125 Date Completed: 20231127 Latest Revision: 20240524

20240524

PMC10675264

10.3390/v15112257

38005933